76 related articles for article (PubMed ID: 2847840)
1. Abnormal responsiveness of nephrogenous cyclic AMP excretion following intravenously administered calcium in normocalcaemic squamous cell cancer patients.
Naafs MA; Hackeng WH; Koorevaar G; Silberbusch J
Bone Miner; 1988 Jul; 4(3):289-98. PubMed ID: 2847840
[TBL] [Abstract][Full Text] [Related]
2. Maximal PTH secretory rate and set point for calcium in normal subjects and patients with primary hyperparathyroidism. In vivo studies.
Gardin JP; Patron P; Fouqueray B; Prigent A; Paillard M
Miner Electrolyte Metab; 1988; 14(4):221-8. PubMed ID: 2850460
[TBL] [Abstract][Full Text] [Related]
3. Nephrogenous cyclic adenosine monophosphate levels in normocalcemic cancer patients: its significance.
Abramson EC; Kukreja SC; Lad TE; Shemerdiak WP; York PA
Horm Metab Res; 1984 Apr; 16(4):204-7. PubMed ID: 6327481
[TBL] [Abstract][Full Text] [Related]
4. Serum ionized calcium, nephrogenous and total urinary cyclic AMP and urinary phosphate in normal subjects.
Thode J; Holmegaard SN; Siggaard-Andersen O
Scand J Clin Lab Invest; 1984 Apr; 44(2):111-8. PubMed ID: 6326252
[TBL] [Abstract][Full Text] [Related]
5. The usefulness of an oral calcium tolerance test in the choice of management of patients with idiopathic hypercalciuria.
Naafs MA; Essed E; Hirdes WH; Hackeng WH; Fischer HR
Neth J Med; 1990 Jun; 36(5-6):223-7. PubMed ID: 2168524
[TBL] [Abstract][Full Text] [Related]
6. Parathyroid hormone does not increase nephrogenous cyclic AMP excretion by the dog.
Fox J; Heath H
Endocrinology; 1980 Dec; 107(6):2124-5. PubMed ID: 6253291
[TBL] [Abstract][Full Text] [Related]
7. End-organ resistance to PTH infusion in hypercalcaemic and normocalcaemic patients with solid tumours.
Naafs MA; Fischer HR; van der Velden PC; Mulder H; Hackeng WH; Schopman W; Koorevaar G; Silberbusch J
Acta Endocrinol (Copenh); 1986 Dec; 113(4):543-50. PubMed ID: 3024441
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenous cyclic adenosine monophosphate as a parathyroid function test.
Broadus AE; Mahaffey JE; Bartter FC; Neer RM
J Clin Invest; 1977 Oct; 60(4):771-83. PubMed ID: 197123
[TBL] [Abstract][Full Text] [Related]
9. The effect of age on the renal response to PTH infusion.
Naafs MA; Fischer HR; Koorevaar G; Hackeng WH; Schopman W; Silberbusch J
Calcif Tissue Int; 1987 Nov; 41(5):262-6. PubMed ID: 2825933
[TBL] [Abstract][Full Text] [Related]
10. Calcium potentiates the cyclic nucleotide and phosphaturic response to parathyroid hormone infusion.
Bikle DD; Herman RH
J Clin Endocrinol Metab; 1983 Jan; 56(1):11-7. PubMed ID: 6292254
[TBL] [Abstract][Full Text] [Related]
11. Effect of intravenous glucagon on the urinary excretion of adenosine 3',5'-monophosphate in man and in rats. Evidence for activation of renal adenylate cyclase and formation of nephrogenous cAMP.
Rubinger D; Wald H; Friedlaender MM; Silver J; Popovtzer MM
Miner Electrolyte Metab; 1988; 14(4):211-20. PubMed ID: 2850459
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of calcium reabsorption observed in advanced breast cancer patients with hypercalcemia and multiple bone metastases.
Kimura S; Adchi I; Yamaguchi K; Suzuki M; Shimada A; Sato Y; Nagaoka K; Abe K
Jpn J Cancer Res; 1985 Apr; 76(4):308-14. PubMed ID: 2989061
[TBL] [Abstract][Full Text] [Related]
13. Urinary cyclic adenosine 3',5'-monophosphate response in McCune-Albright syndrome: clinical evidence for altered renal adenylate cyclase activity.
Zung A; Chalew SA; Schwindinger WF; Levine MA; Phillip M; Jara A; Counts DR; Kowarski AA
J Clin Endocrinol Metab; 1995 Dec; 80(12):3576-81. PubMed ID: 8530601
[TBL] [Abstract][Full Text] [Related]
14. Changes in nephrogenous cyclic AMP excretion and plasma cyclic AMP following treatment of hyperthyroidism.
Naafs MA; van der Velden PC; Fischer HR; Koorevaar G; van Duin S; Hackeng WH; Schopman W; Silberbusch J
Acta Endocrinol (Copenh); 1984 Aug; 106(4):477-81. PubMed ID: 6206676
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of the determination of nephrogenous cyclic AMP in the diagnosis of primary hyperparathyroidism].
Bill G; Jacquet AF; Burckhardt P
Schweiz Med Wochenschr; 1983 Mar; 113(9):327-30. PubMed ID: 6302835
[TBL] [Abstract][Full Text] [Related]
16. Rapid development of renal resistance to low doses of synthetic bovine parathyroid hormone fragment 1-34. Dissociation of urinary cyclic adenosine monophosphate, phosphaturic, and calciuric responses.
Law WM; Heath H
J Clin Invest; 1983 Sep; 72(3):1106-13. PubMed ID: 6309905
[TBL] [Abstract][Full Text] [Related]
17. Effects of parathyroid hormone and calcitonin on stop-flow patterns of cyclic AMP, sodium, potassium, calcium and inorganic phosphate in thyroparathyroidectomized rabbits.
Tabei K; Asano Y; Imai M
Miner Electrolyte Metab; 1984; 10(1):36-42. PubMed ID: 6330514
[TBL] [Abstract][Full Text] [Related]
18. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy.
Fraser WD; Logue FC; Gallacher SJ; O'Reilly DS; Beastall GH; Ralston SH; Boyle IT
Bone Miner; 1991 Feb; 12(2):113-21. PubMed ID: 1849762
[TBL] [Abstract][Full Text] [Related]
19. Effects of the intravenous administration of calcium on nephrogenous cyclic AMP: use as a parathyroid suppression test.
Broadus AE; Deftos LJ; Bartter FC
J Clin Endocrinol Metab; 1978 Mar; 46(3):477-87. PubMed ID: 221521
[TBL] [Abstract][Full Text] [Related]
20. Gender variation in PTH sensitivity and rhythmicity following growth hormone replacement in adult growth hormone-deficient patients.
White HD; Ahmad AM; Syed AA; Clewes A; Peter R; Vora JP; Fraser WD
Clin Endocrinol (Oxf); 2004 Apr; 60(4):516-26. PubMed ID: 15049968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
